January 05, 2024

The U.S. Food and Drug Administration (FDA) has greenlit Florida's Agency for Health Care Administration's drug importation initiative, marking a significant move in pharmaceutical policy. Under section 804 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), this approval sets the stage for Florida to proceed with importing select prescription drugs from Canada. President Biden's directive on enhancing competition in the American economy spurred this action, urging collaboration between the FDA and states to drive down costs for consumers while upholding safety standards.

Florida's program operates under a two-year authorization period from the FDA's notification of the inaugural drug shipment for importation. Integral to this process, the state's Agency for Health Care Administration must adhere to several prerequisites:

Moreover, quarterly reports to the FDA are mandated, encompassing information on imported drugs, cost savings, and any identified safety or quality issues.

FDA Commissioner Robert M. Califf, M.D., emphasized the agency's commitment to collaborating with states and tribes on importation initiatives. The FDA will provide oversight to ensure Florida's compliance with section 804 of the FD&C Act and relevant regulations. Florida must maintain supply chain integrity, monitor adverse events, adhere to recall procedures, and report quarterly to the FDA.

States and tribes are encouraged to submit Section 804 Importation Program (SIP) proposals to the FDA, subject to thorough review and authorization criteria outlined by the FD&C Act and FDA regulations. The FDA offers guidance, including a small entity compliance Q&A guide and tips for SIPs, to facilitate proposal development.

This authorization underscores a pivotal shift in drug importation policy, reflecting efforts to enhance accessibility and affordability for American consumers while prioritizing safety and regulatory compliance.